论文部分内容阅读
默克公司向美国ＦＤＡ提交它的消炎药，ＣＯＸ－２选择性抑制剂ｒｏｆｅｃｏｘｉｂ（Ｖｉｏｘｘ），作为骨关节炎和疼痛治疗的新药申请。公司说，这是该药的首次申请，预计年底将在世界范围内申请上市。ｒｏｆｅｃｏｘｉｂ是ＣＯＸ－２选择性抑制剂的第２个新药，另一个是西尔?
Merck submitted its anti-inflammatory drug, the COX-2 selective inhibitor rofecoxib (Vioxx), to the U.S. FDA for its new drug application for the treatment of osteoarthritis and pain. The company said it is the first application for the drug and is expected to apply for listing worldwide by the end of the year. rofecoxib is a COX-2 selective inhibitor of the second new drug, the other is acer?